Transfer Membrane Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Transfer Membrane Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Transfer Membrane Market is expected to register a CAGR of 1.5% over the forecast period.

The emergence of new and evolving SARS-CoV-2 variants has fueled the need for change in the form of innovative and more adaptable diagnostic approaches for SARS-CoV-2 infection detection. On the other hand, due to new variations and variable symptoms across infected persons, creating rapid and sensitive testing tools has become increasingly difficult. Vaccines are also still the most important tool for infection prevention and protection. According to the study "Emerging COVID-19 Variants and their Impact on SARS-CoV-2 Diagnosis, Therapeutics and Vaccines" published in the Journal of "Annals of Medicines" in February 2022, novel vaccines and medicines are continually being explored to elicit an immune response capable of effectively targeting SARS-CoV-2 and its variations. The significant advancement of better diagnostics, targeted vaccines, and therapeutic therapies demonstrates that scientific knowledge, research, and technology are advancing at the same rate as the pandemic. Thus, further study is needed to improve the understanding of critical aspects of viral pathogenesis, which can lead to better preventive and treatment measures. Such studies show the need for new therapeutics for targeting diseases, in turn, the demand for transfer membrane is expected to increase among end users as it is used in the detection and analysis of proteins and nucleic acids. Therefore, it is expected to have a significant impact on the target industry during the forecast period.

The market is primarily driven by the increasing investment in R&D by pharmaceutical and biopharmaceutical companies and the development of new therapeutics for targeting chronic diseases. For instance, according to the European Commission Industrial R&D Investment prediction, data updated in December 2021, the United States will spend more than USD 679 billion on research and development in 2022. It is anticipated that China will spend roughly USD 551.1 billion on R&D in 2022.

Furthermore, the growing prevalence of autoimmune diseases, and infectious diseases, and the increasing focus on the development of novel drug therapies based on DNA and RNA are projected to boost market growth over the forecast period. As per the study "Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries" published in April 2021, an estimate of the number of systemic lupus erythematosus cases in the United States was 72.8 per 100,000 person-years. Therefore, the growing prevalence rate of autoimmune diseases is expected to increase the R&D activities, in turn, the demand for transfer membranes is anticipated to upsurge. Eventually, these factors are expected to fuel the target market growth over the forecast period.

However, the availability of alternative methods for protein transfer with high efficiency and automation is anticipated to hamper the market growth.

Key Market TrendsWestern Blotting Segment Expected to have Lucrative Growth Over the Forecast Period

Western blotting is a widely known and used test in cell and molecular biology. The test helps to detect the specific type of protein from the complex mixture of proteins that are extracted from the cell. This test has gained attraction in the market due to its specificity, low cost, and ease of use. Western blot test is having a wide range of applications in medical diagnostics such as diagnosis of diseases such as BSE (Bovine Spongiform Encephalopathy), FIV (Feline Immunodeficiency Virus), HBV (Hepatitis B Virus) infection, and Lyme Disease among others. Generally, this test is used as a confirmatory test for the above-mentioned diseases after the ELISA test is done with a positive result. For instance, in July 2020, for Lyme Disease, the United States Food and Drug Administration (FDA) suggested that the two-tier protocol use an ELISA test initially and then the specific western blot test for the confirmation of diagnosis if the results of the ELISA were positive. Hence, these factors will have a positive impact on the target market over the studied period.

Previously, western blotting was commonly done to confirm the HIV diagnosis. However, the Centre for Disease Control and Prevention (CDC) in the year has recommended discontinuing the Western blot test for HIV as there are novel techniques that came up in the market for HIV detection. Furthermore, studies have suggested that western blot is a priority test for the diagnosis of diseases such as BSE (Bovine Spongiform Encephalopathy), and FIV (Feline Immunodeficiency Virus). Therefore, due to the above-mentioned factors, it is projected that target segment will witness a high CAGR during the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

The North American region is anticipated to have a significant market share owing to a large number of R&D activities, huge investments in developing new drugs, and support from the public and private organizations for research. Moreover, the growing prevalence of chronic diseases coupled with rising targeted diseases in the region is anticipated to boost regional growth. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the United States in 2020, with nearly 612,390 deaths. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the United States. Hence, Such a factor will positively influence the target market growth in the forecasted period.

Research and development budgets of pharmaceutical companies have also increased in the last few years, owing to the increasing focus on regulating markets, complex molecules, and therapy segments. In the United States, pharmaceutical companies spend more money, time, and energy on R&D than others. According to the 2021 PhRMA Annual Membership Survey, the total amount spent on research and development (R&D) by its member companies is expected to reach USD 91 billion by 2020. Therefore, the rise in research & development activities in the region is expected to increase the demand for transfer membranes, which, in turn, is expected to aid the growth of the market studied in the region over the forecast period.

Competitive Landscape

The transfer membrane market is moderately competitive with the presence of a few key players operating in the market including Merck KGaA, PerkinElmer, Inc., Pall Corporation, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., Abcam plc, General Electric, Santa Cruz Biotechnology, Inc., Axiva Sichem Biotech, Macherey-Nagel, GE Healthcare, and ATTO Corporation.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.